Form 4: enGene Holdings Inc. Executive Acquires Stock Options
SEC Form 4
Anthony T. Cheung, Chief Scientific Officer of enGene Holdings Inc., reports the acquisition of stock options.
Summary
- Anthony T. Cheung, the Chief Scientific Officer of enGene Holdings Inc., filed a Form 4 to report changes in beneficial ownership.
- On January 29, 2025, Cheung acquired 250,000 stock options with an exercise price of $7.39.
- These options vest monthly over 48 months, contingent upon continued service, and expire on January 29, 2035.
- Following the transaction, Cheung directly owns 250,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition, which is a common form of executive compensation.
Positives
- The acquisition of stock options by a key executive could signal confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track executive compensation and potential alignment of interests.
Stakeholder Impact
- The acquisition of stock options by the Chief Scientific Officer may align his interests with those of shareholders, potentially encouraging decisions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 01/29/2025 | Date of stock option acquisition |
| 01/31/2025 | Date of Form 4 filing |
| 01/29/2035 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.